Clay co-founded PhaseBio Pharmaceuticals in 2002 and has served as a member of the company’s board of directors since that time. He has served as Chairman of PhaseBio since November 2014. Since 1995, Clay has co-founded seven life sciences companies, including PhaseBio. He also co-founded Hatteras Venture Partners in 2000, where he has been instrumental in building the firm from its origins with a $3 million seed fund to a venture capital partnership that manages over $350 million across five funds. Clay was co-founder, CEO and Chairman of Synthematix, Inc., a chemistry informatics company acquired in April 2005 by Symyx Technologies. He was the co-founder and Head of Corporate Development for Novalon Pharmaceutical Corporation, where he led financing efforts and was Head of Business Development from inception until Novalon’s sale to Karo Bio for $106.7 million in May 2000. Prior to Novalon, Clay was the co-founder and President of Xanthon, Inc., a bioinformatics company with electro-chemical detection technology for direct analysis of DNA, RNA and proteins. Clay currently serves as Chairman of GeneCentric Diagnostics and on the boards of Clearside Biomedical, Curoverse, Lysosomal Therapeutics and Orig3n. He received a BA in mathematics and art history from the University of North Carolina at Chapel Hill and a Masters of Public Policy from Harvard University.